Products & Services Overview

In therapeutic drug development, the ultimate challenge is demonstrating efficacy balanced with safety.

Protein and small molecule biomarkers hold significant promise to streamline and improve the output of drug development programs. However, technical limitations prevent developers from detecting and accurately measuring biomarker levels in healthy individuals and precisely quantifying the small changes that may be associated with disease pathology or therapeutic benefit.

Singulex answers this problem by coupling robust immunoassays to proprietary technology that improves assay sensitivity and extends dynamic range ten to one thousand times farther than could be achieved before. With the Erenna Immunoassay System, even the smallest changes in biomarker levels can be measured, allowing drug developers to gain unprecedented insights about compound efficacy and safety.

Now, through the Singulex Erenna Technology Access Program (ETAP), select partners can access this technology as well as Singulex’s assay menu and expertise in custom assay development and sample analysis.

To read More Click Here.